Janssen Pharmaceutica NV /
Kineta
Janssen Pharmaceutica NV buys Kineta, Inc. product rights
- Price
- $26.0m
- Stage
- Closed
What happened
Janssen Pharmaceutica NV paid $26.0 million in cash for Kineta, Inc.’s rights to YTX-7739 and its unpartnered pre-clinical and discovery-stage product candidates, along with related intellectual property rights. The sale was completed on Dec. 14, 2022.
The source
Everything on this page comes from the source below.
Janssen Pharmaceutica NV buys Kineta, Inc. product rights
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly